Pharmacokinetics of micafungin in critically ill patients with invasive candidiasis.

Pharmacokinetics of micafungin in critically ill patients with invasive candidiasis. - Pharmacokinetics of micafungin.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37779

Enrollment

Registered

2012-08-03

Start date

2012-12-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive candidiasis invasive fungal infection

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Treatment with micafungin Admission to an ICU Age >= 18 years Invasive candidiasis

Exclusion criteria

Exclusion criteria: Blood sampling not possible.

Design outcomes

Primary

Measure	Time frame
The main study parameter is the correlation of the pharmacokinetic parameters and plasma concentration of micafungin with disease severity scores.	—

Secondary

Measure	Time frame
1) Pharmacokinetic parameters of micafungin in ICU patients. 2) Time (in days) to culture conversion. 3) Correlation of the plasma concentration of micafungin with response to treatment. 4) Correlation of the plasma concentration of micafungin with inflammation parameters. 5) AUC/MIC ratio and Cmax/MIC ratio. 6) Constructing a pharmacokinetic model of micafungin in critically ill patients.	—

Countries

Netherlands

Outcome results